regarding significance B of log2 H/L ratios (taking into account summed protein intensity and normalized H/L ratios) and GO annotation of gene names using the Perseus software package (http://www.perseusframework.org/). Identified proteins were considered "hits" according to the following criteria: (a) when they showed a B significant H/L ratio in at least one of the four pull down experiments (quadruplicates), (b) when they were quantified in at least three out of four pull down experiments and (c) when they passed the Students T-test with a p-value <0.05. Exceptions were made were no more than one outlying H/L value caused the p-value to exceed the <0.05 threshold. No p-values were calculated for "hits" which were only quantified in three out of four experiments. These were assigned as not applicable (na) in ESI Excel file 2.
General materials and methods for synthesis
Unless noted otherwise all reagents were obtained from commercial suppliers and used as received. 1 H-NMR spectra were measured on a Bruker AV-300 or Bruker AV-301 instrument. Chemical shifts are reported in ppm and coupling constants are reported in Hz. Mass spectrometry of the small molecule compounds was performed on a Bruker Esquire Ion Trap MS instrument. For RP-HPLC purification samples were injected on a preparative reverse-phase C 18 column (250 x 21 mm) and run over 60 min. at 8 mL/min. (MeCN/H2O containing 0.05 v% TFA, gradient: 1:99 to 100:0). Purified products were detected by UV (254 nm). Analytical HPLC samples were run on a C 18 column (150 x 2.1 mm) with MeCN/H2O containing 0.05 v% TFA and a gradient of 1:99 to 100:0 over 30 min. at a flow rate of 1ml/min. Bands were detected at 254 nM. Compounds used for our experiments were generally of 95% purity or higher.
Sepharose affinity resins were prepared as reported previously 2 . Bead loading was determined by measuring the depletion of the affinity reagent from the supernatant by analytical HPLC. Generally the loading was found to be between 0.8 mM and 0.5 mM of the affinity reagent (calculated for 50 v% bead slurry).
Type II inhibitor fragment S5 and tert-butyl (2-(4-((6-bromoquinazolin-2-yl)amino)phenoxy)ethyl)carbamate S3 3 , the dasatinib amine analog S2 4 , and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)acetic acid 5 were synthesized according to the published protocols.
General procedure for amide couplings A:
The amine, either as its free base or its TFA-salt was dissolved in dry DMF at a final concentration of approx. 50 mM under an atmosphere of nitrogen. The corresponding carboxylic acid (1.5 eq), HOAt (1.5 eq), and DIPEA (1.5 eq for coupling of free bases and 3 eq for coupling of TFA-salts) were added and the mixture cooled in an ice-water bath. EDC was added and the mixture stirred for 2 h at 4°C and another 12 h at rt. The mixture was diluted with the 10-fold volume of EtOAc and transferred to a separatory funnel. The organic phase was washed 2x with 1 M aq. NaOH, 2x with 0.5 M aq. NaH2PO4, 1x with brine, dried over MgSO4 and the solvent removed at the rotary evaporator. The residual crude amide was purified by column chromatography under the conditions indicated below.
General procedure for Suzuki couplings B

:
A sealable thick-walled glass tube equipped with a stirring bar was charged with the corresponding bromide (1 eq) and a mixture of DME-water 4:1 v/v to give a solution of 0.2 M final concentration. The aryl boronic acid derivative (2 eq), Na2CO3 (2 eq for coupling of free amines and 4 eq. for ammonium compounds), Pd(OAc)2 dimer (0.01 eq) and P(o-Tol)3 (0.02 eq) were added and the tube sealed with a septum cap. The vessel was evacuated and flushed with nitrogen alternately five times. The slurry was then heated for 90 min. at 85 °C in an oil bath with vigorous stirring. After completion of the reaction the residue was diluted with 20 times the volume EtOAc and transferred to a separatory funnel. The organic layer was washed once with 1 M NaOH, once with sat. NaHCO3 and once with brine, dried over MgSO4 and the solvent removed at the rotary evaporator. The residual crude product was purified by column chromatography under the conditions indicated below.
General procedure for deprotection of N-Boc-protected amines C:
In a round bottom flask equipped with a stirring bar the corresponding N-Boc-protected amine was dissolved in a mixture of dry DCM/TFA 4:1 v/v at a concentration of approx. 0.16 M. The solution was stirred for 1 h at RT and the volatiles then removed in a stream of air. The residual TFA salts were dried in high vacuum overnight and used for the synthesis of follow-up compounds without further purification.
Synthesis of the affinity reagents
Synthesis of 2,2-dimethyl-4,9-dioxo-3,12,15-trioxa-5,8-diazaoctadecan-18-oic acid (S1): Commercially available 3-(2-(3-ethoxy-3-oxopropoxy)ethoxy)propanoic acid (250 mg, 1.07 mmol) was coupled to NBoc-ethylenediamine following general procedure A yielding the crude ethyl ester amide (358 mg, 0.95 mmol, 89%) as a colorless oil. The crude ester was dissolved in 6 ml MeOH and 2.85 ml of a 1 M aq. NaOH soln. were added. The mixture was stirred for 2 h at rt and then MeOH removed at the rotary evaporator. The residual solution was saturated with NaCl, brought to pH 2 with 1 M aq. HCl and transferred to a separatory funnel. The aqueous layer was extracted 5x with 5 ml DCM each, the organic layer dried over MgSO4 and the solvent removed at the rotary evaporator. Title compound S1 was obtained as a colorless oil and used for follow up syntheses without further purification. ESI-MS: m/z = 347.
Synthesis of 2-((6-(4-(14-amino-4-oxo-6,9,12-trioxa-3-azatetradecyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (3):
Dasatinib amine derivative S2 (20 mg, 41.4 µmol) was coupled to 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)acetic acid according to the standard procedure A. The crude azide (27.6 mg, 39.3 µmol) was then dissolved in 1 ml THF/H20 4:1 v/v and PPh3 (20.6 mg ,78.6 µmol, 2eq) was added. The mixture was stirred for 24 h at rt and the solvent removed at the rotary evaporator. The residual crude product was subjected to column chromatography eluting with + . 
Synthesis of tert-butyl (2-(4-((6-(3-aminophenyl)quinazolin-2-yl)amino)phenoxy)ethyl)carbamate
Synthesis of tert-butyl (2-(4-((6-(3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl)quinazolin-2-yl)amino)phenoxy)-ethyl)carbamate (S9)
: m-Aniline S6 (7.5 mg, 15.9 µmol) was dissolved in 0.5 ml dry THF under an atmosphere of nitrogen. The soln. was cooled to 4°C in an ice-water bath and 1-isocyanato-3-(trifluoromethyl)benzene (4.4 µl, 31.8 µmol, 2 eq) was added. The mixture was stirred for 1 h at 4°C and an additional 2 h at rt. Then the solvent was removed at the rotary evaporator and the residue subjected to silica gel column chromatography eluting with EtOAc/hexane 3:2 v/v. This gave the pure title compound S9 (9.84 mg, 19.4 µmol, 94%) as a light yellow resin. 
Synthesis of tert-butyl (2-(4-((6-(4-(3-(trifluoromethyl)benzamido)phenyl)quinazolin-2-yl)amino)phenoxy)ethyl)-carbamate (S10):
p-Aniline S7 (7.5 mg, 15.9 µmol) was coupled to 3-(trifluoromethyl)benzoic acid according to the general procedure A. Silica gel column chromatography eluting with EtOAc/hexanes 2:3 v/v gave the pure title compound S10 ( 8.49 mg, 13.2 µmol, 83%) as a light yellow resin. (4) : N-Boc-protected precursor S5 (20 mg, 30.4 µmol) was treated according to the general procedure C. The corresponding crude TFA salt of S5 was then coupled to linker S1 according to the general procedure A. The crude product was subjected to silica gel column chromatography eluting with CHCl3 containing 4 v% MeOH to give the N-Bocprotected precursor as a yellow resin which was directly subjected to N-Boc-deprotection according to general procedure C. (5) : N-Boc-protected precursor S4 (15 mg, 27.1 µmol)was treated according to the general procedure C. The corresponding crude TFA salt of S4 was then coupled to linker S1 according to the general procedure A. The crude product was subjected to silica gel column chromatography eluting with CHCl3 containing 4 v% MeOH to give the N-Boc-protected precursor as a faint yellow resin which was directly subjected to N-Boc-deprotection according to general procedure C. Pure title compound 5 (17.1 mg, 21.4 µmol, 79 %) was obtained as a faint orange resin. ((16-amino-4,13-dioxo-7,10-dioxa-3,14-diazahexadecyl) (6) : N-Boc-protected precursor S8 (20 mg, 31.1 µmol) was treated according to the general procedure C. The corresponding crude TFA salt of S8 was then coupled to linker S1 according to the general procedure A. The crude product was subjected to silica gel column chromatography eluting with CHCl3 containing 4 v% MeOH to give the N-Boc-protected precursor as a yellow resin which was directly subjected to N-Boc-deprotection according to general procedure C. Pure title compound 6 (23.7 mg, 26.7 µmol, 86%) was obtained as an orange resin. (8) : N-Boc-protected precursor S9 (20 mg, 30.4 µmol) was treated according to the general procedure C. The corresponding crude TFA salt of S9 was then coupled to linker S1 according to the general procedure A. The crude product was subjected to silica gel column chromatography eluting with CHCl3 containing 5 v% MeOH to give the N-Boc-protected precursor as a yellow resin which was directly subjected to N-Boc-deprotection according to general procedure C. Pure title compound 8 (24.4 mg, 27.0 µmol, 89%) was obtained as an orange resin. (7) : N-Boc-protected precursor S10 (20 mg, 31.1 µmol) was treated according to the general procedure C. The corresponding crude TFA salt of S10 was then coupled to linker S1 according to the general procedure A. The crude product was subjected to silica gel column chromatography eluting with CHCl3 containing 5 v% MeOH to give the N-Boc-protected precursor as a yellow resin which was directly subjected to N-Boc-deprotection according to general procedure C. Pure title compound 7 ( 19.6 mg, 22.1 µmol, 71%) was obtained as an orange resin. 
Synthesis of N-(3-(2-((4-((16-amino-4,13-dioxo-7,10-dioxa-3,14-diazahexadecyl)oxy)phenyl)amino)quinazolin-6-yl)-
4-methylphenyl)-3-(trifluoromethyl)benzamide trifluoroacetic acid salt
Synthesis of N-(3-(2-((4-((16-amino-4,13-dioxo-7,10-dioxa-3,14-diazahexadecyl)oxy)phenyl)amino)quinazolin-6-yl)-4-methylphenyl)cyclopropanecarboxamide trifluoroacetic acid salt
Synthesis of N-(3-(2-((4-
oxy)phenyl)amino)quinazolin-6-yl)phenyl)-3-(trifluoromethyl)benzamide trifluoroacetic acid salt
Synthesis of N-(2-aminoethyl)-3-(2-(3-oxo-3-((2-(4-((6-(3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl)quinazolin-2-yl)amino)phenoxy)ethyl)amino)propoxy)ethoxy)propanamide trifluoroacetic acid salt
Synthesis of N-(4-(2-((4-((16-amino-4,13-dioxo-7,10-dioxa-3,14-diazahexadecyl)oxy)phenyl)amino)quinazolin-6-yl)phenyl)-3-(trifluoromethyl)benzamide trifluoroacetic acid salt
